Moreover, increased CCAR1 protein expression in HCC cells promotes the transcription of PD-L1 by binding β-catenin, which may enhance the resistance for anti-PD1 therapy (Fig. 9J). The gene discussed is CCAR1; the disease is hepatocellular carcinoma.